Trulicity Injection, Solution
Product Images NDC 50090-6571

Product Visual Gallery

This gallery contains 48 technical images submitted to the FDA as part of the official labeling for Trulicity (NDC 50090-6571). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906571)

The label for TRULICITY (dulaglutide) injection, solution by A-S Medication Solutions, displays the 3 mg/0.5 mL strength. It indicates a once-weekly dosing schedule and refrigeration instructions (36 to 46 degrees F). The package contains four single-dose pens with NDC 50090-6571-0 and the product number 9945-0.*

FDA Label Image

Logo (Logo)

FDA Label Image

Qr Code (Qr V1)

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites Back V1)

An anatomical illustration showing the recommended subcutaneous injection sites for TRULICITY (dulaglutide) on the outer upper arms of a human figure from the rear view. The injection areas on both outer upper arms are highlighted in yellow.*

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites Front V1)

An illustration showing a front view of a human figure highlighting recommended subcutaneous injection sites for medication. The areas marked in yellow are the abdomen around the navel and the front upper thighs, indicating suitable locations for injection administration.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites Back V1)

An anatomical diagram of a human figure viewed from the back, highlighting the outer upper arm areas on both sides in blue, indicating recommended subcutaneous injection sites.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites Front V1)

An illustration showing a front view of a human figure highlighting recommended subcutaneous injection sites for TRULICITY (Dulaglutide) 3 mg/0.5 mL injection. The highlighted injection areas are the abdomen (around the navel) and the front of both thighs.*

FDA Label Image

Figure (Trulicity Ifu 3mg Injection Sites V1)

An anatomical illustration showing recommended subcutaneous injection sites on the human body. Shaded areas indicate the abdomen, upper arms, and front and back of the thighs as suitable areas for injection.*

FDA Label Image

Figure (Trulicity Ifu 4point5mg Injection Sites V1)

An instructional diagram showing recommended subcutaneous injection sites on a human body. Highlighted areas include the abdomen, upper arms, and outer thighs. The image features front and back views with green shaded regions indicating the appropriate injection sites for the medication.*

FDA Label Image

Figure (Trulicity Ifu Check V1)

FDA Label Image

Exclamation (Trulicity Ifu Exclamation V1)

TRULICITY 3 mg/0.5 mL injection, solution in a single-dose prefilled pen for subcutaneous use. The label shows the proprietary name TRULICITY prominently, with the generic name Dulaglutide beneath it. Manufacturer is A-S Medication Solutions. The label includes dose strength and NDC number 50090-6571.*

FDA Label Image

Figure (Trulicity Ifu Expiration Location V2)

Illustration showing the location of the expiration date on a TRULICITY 3 mg/.5 mL single-dose injection pen. The expiration date is indicated by a label marked with a red arrow pointing to a black rectangular area near the pen's plunger end.*

FDA Label Image

Figure (Trulicity Ifu Inspect V1)

FDA Label Image

Locked (Trulicity Ifu Locked V1)

TRULICITY 3 mg/0.5 mL injection, solution in a prefilled pen for subcutaneous use. The packaging shows the A-S Medication Solutions labeler and Product NDC 50090-6571. The label includes dosage details and visual branding for TRULICITY Dulaglutide.*

FDA Label Image

Figure (Trulicity Ifu Prepare V1)

FDA Label Image

Figure (Trulicity Ifu Remove V1)

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F2 V3)

An instructional illustration showing a hand holding a TRULICITY (dulaglutide) injection pen with another hand removing a black cap from the pen. The image directs the user to pull the cap downward as part of the preparation steps for subcutaneous injection.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F3 V3)

An instructional illustration showing a person holding a TRULICITY injection pen, preparing to administer a subcutaneous injection by activating the pen's mechanism. The image focuses on hand placement and handling of the injection device.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F4 V3)

An instructional illustration showing the proper use of a prefilled injection device. The image depicts a person holding the device against the skin for 5-10 seconds during administration, with a close-up inset highlighting the injection device tip for clarity.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F5 V3)

An instructional illustration showing a hand holding a prefilled syringe labeled as TRULICITY (dulaglutide) injection solution. The syringe is positioned above a biohazard sharps disposal container, demonstrating safe disposal of the syringe after use.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen Parts V3)

An illustrated diagram of the TRULICITY (dulaglutide) injection pen showing labeled parts including the injection button, lock ring, indicator, lock/unlock feature, medicine reservoir, clear base, and base cap. The diagram is oriented with the top and bottom (needle end) indicated.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen V3)

TRULICITY 3 mg/0.5 mL subcutaneous injection pen by A-S Medication Solutions. The pen device is primarily white with a distinctive purple and yellow label wrap. The end cap is green, and the opposite end features a gray needle cover. The device includes an indicator window near the green cap.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F2 V3)

Instructional illustration showing a hand holding a TRULICITY (Dulaglutide) injection pen vertically, with the other hand holding the black needle cap below it. A downward arrow indicates the step of removing or attaching the needle cap from the injection pen, demonstrating part of the injection preparation process.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F3 V3)

An instructional illustration showing how to use the TRULICITY injection pen, demonstrating the user holding the pen and preparing to administer a subcutaneous injection into the abdomen area with a rotation arrow indicating the step to follow.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F4 V3)

Instructional illustration showing how to prepare and administer a subcutaneous injection using a prefilled syringe. The image depicts a person holding the syringe with the needle inserted into the skin for 5 to 10 seconds and includes a close-up view of the syringe tip to guide proper use.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F5 V3)

An instructional illustration showing a hand holding a prefilled syringe above a biohazard sharps disposal container, demonstrating proper disposal of the syringe after use.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen Parts V3)

An instructional diagram of a TRULICITY (Dulaglutide) injection pen showing its components, including the injection button, lock ring, indicator with lock/unlock symbols, medicine cartridge, clear base, and base cap. Labels point to each part to guide users on the device's anatomy.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen V3)

TRULICITY 3 mg/0.5 mL injection pen is a subcutaneous dose delivery device. The pen has a white body with a blue and purple geometric design, a green button on one end, and a gray cap on the other. It is labeled by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F2 V1)

An instructional diagram showing a hand holding a TRULICITY injection pen with a green button on top. Another hand is shown removing or attaching a black cap from the bottom of the pen, indicated by a downward arrow. The image suggests a step in preparing the injection device for use.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F3 V1)

An instructional illustration showing hands using a prefilled pen injector, likely demonstrating the injection process of a medication. The image highlights twisting or turning motions on the pen's green end, indicating steps in preparing or administering a subcutaneous injection.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F4 V1)

Illustration showing the use of a subcutaneous injection pen for TRULICITY (dulaglutide) 3 mg/.5 mL. The image instructs the user to hold the injection for 5-10 seconds and indicates that the injection is complete when the gray plunger is visible. The injection is depicted being administered to the thigh.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F5 V1)

An illustration showing a hand holding a syringe above a biohazard sharps disposal container. The image depicts proper disposal of the syringe immediately after injection to ensure safe handling of medical waste.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen Parts V1)

An instructional illustration of a TRULICITY (Dulaglutide) 3 mg/0.5 mL injection pen showing labeled parts including the injection button, lock ring, indicator, lock/unlock icons, medicine chamber, clear base, and base cap. The image depicts the pen orientation with top and bottom needle end directions.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen V1)

TRULICITY 3 mg/0.5 mL injection, solution in a prefilled, single-use pen device for subcutaneous administration. The pen is predominantly white with a purple accent and features a transparent cartridge section, a green dose button on the cap end, and a gray needle guard at the opposite end. Labeler is A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F2 V1)

An illustrated instructional diagram showing hands holding a TRULICITY (Dulaglutide) injection pen and a needle cap, with a downward arrow indicating the removal or attachment of the needle cap to the pen. The image outlines a step in preparing the injection device for subcutaneous administration.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F3 V1)

An instructional illustration showing hands administering a subcutaneous injection with a prefilled pen. One hand holds the pen at the injection site on the abdomen, while the other hand turns the green cap or dial on the pen. A green unlocked padlock icon appears in the upper left corner, indicating the pen is unlocked and ready for use.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F4 V1)

An instructional illustration showing how to correctly administer a subcutaneous injection with the TRULICITY 3 mg/0.5 mL single-dose pen. It highlights holding the pen in position for 5 to 10 seconds and indicates that the injection is complete when the gray plunger becomes visible.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F5 V1)

Illustration showing a hand disposing of a used syringe into a sharps container marked with a biohazard symbol. The syringe is held above the container's open lid, demonstrating safe disposal practices for injection devices.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen Parts V1)

An instructional diagram of a TRULICITY injection pen showing labeled parts including the Injection Button, Lock Ring, Indicator, Lock/Unlock symbols, Medicine window, Clear Base, and Base Cap. The direction markers for the top and bottom/needle end are also indicated.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen V1)

TRULICITY 3 mg/0.5 mL subcutaneous injection pen, containing dulaglutide, shown as a single-use prefilled syringe pen. The pen features a transparent needle cover, a white body with purple and green labeling elements, and a green cap at the end. It is labeled by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Unfold V1)

An instructional diagram showing a folded, accordion-style paper unfolded and laid flat. The image includes arrows indicating the folding direction and text advising to read both sides for full instructions. This likely accompanies a medication guide or patient information leaflet.*

FDA Label Image

Unlocked (Trulicity Ifu Unlock V1)

TRULICITY 3 mg/0.5 mL injection solution in a single-dose pre-filled pen for subcutaneous use. The label includes dosage strength and route, with the labeler identified as A-S Medication Solutions. The design features branding and regulatory information consistent with human prescription drug packaging.*

FDA Label Image

Figure 1 (Trulicity Pi F1 V2)

A pharmacokinetic chart illustrating the ratio and 90% confidence intervals for AUC and Cmax values relative to reference across various intrinsic factors, including weight, age, sex, race, renal impairment, and hepatic impairment. Markers show how these factors impact drug exposure compared to a standard reference, with a horizontal axis representing the ratio relative to reference ranging from 0.0 to 2.0.*

FDA Label Image

Figure 2 (Trulicity Pi F2 V2)

A pharmacokinetic (PK) chart showing the ratio and 90% confidence intervals for AUC and Cmax values of various coadministered drugs relative to a reference. Drugs listed include Lisinopril, Metoprolol, Digoxin, Norelgestromin, Ethinylestradiol, Atorvastatin, Metformin, Acetaminophen, S-Warfarin, R-Warfarin, and Sitagliptin. The X-axis represents the ratio relative to reference from 0.0 to 2.0.*

FDA Label Image

Figure 3 (Trulicity Pi F3 V3)

A line graph showing LS mean HbA1c (%) over weeks post-randomization for four groups: TRULICITY 1.5 mg, TRULICITY 0.75 mg, Sitagliptin 100 mg, and Placebo. The x-axis represents weeks (0 to 52), and the y-axis represents HbA1c percent (6.6 to 8.4). Data points and error bars indicate changes in HbA1c levels across time for each group.*

FDA Label Image

Figure 4 (Trulicity Pi F4 V3)

A line graph showing mean HbA1c percentage over weeks post-randomization for TRULICITY injection solutions at 1.5 mg, 3 mg, and 4.5 mg doses. The x-axis denotes weeks (baseline to week 36), and the y-axis denotes mean HbA1c (%). All doses show a decline in HbA1c over time with slight variations among the dose levels.*

FDA Label Image

Figure 5 (Trulicity Pi F5 V2)

Line graph depicting the least squares mean HbA1c percentages over 26 weeks post-randomization comparing TRULICITY 1.5 mg, TRULICITY 0.75 mg, Exenatide, and placebo groups. The x-axis shows time in weeks, and the y-axis shows HbA1c percentage values.*

FDA Label Image

Figure 6 (Trulicity Pi F6 V2)

A line graph showing the percentage of patients with an event over time from randomization in years, comparing Dulaglutide and placebo groups. The vertical axis represents patients with an event (%) from 0 to 20, and the horizontal axis spans 0 to 6 years. Two lines, one for placebo and one for Dulaglutide, track event rates with Dulaglutide showing a slightly lower percentage over time. Hazard ratio (HR) of 0.88 with 95% confidence interval [0.79, 0.99] is noted on the chart.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.